An unmet medical need…
COPD | Asthma |
---|---|
Characterized by airflow obstruction and airway inflammation |
Characterized by episodes of airway narrowing in response to asthma triggers |
Prevalence of ~16 Million in US | Prevalence of 25.1 Million in US |
Addressable market of ~4 M in US | Addressable market of 2.5 M in US |
133,575 deaths, 10.3 million physician office visits, 699,000 hospitalizations annually | 4000 deaths, 12.8 million physician office visits, 1.8 million emergency room visits annually |
…A large market potential
Market Potential
~16 Million US patients with COPD
- ~25% of these are candidates for AerWave Medical, Inc. treatment
~ 25 Million US patients with asthma
- > 25% of the would benefit from AerWave Medical, Inc. treatment
~ 65 Million patients with moderate to severe COPD worldwide
Addressable Market
- Addressable COPD market of ~4 Million patients in US
- Addressable Asthma market of 2.5 Million patients in US
Data shows 84% reduction in hospital visits for COPD patients after lung denervation